Data / Drug companies / Camber Consumer Care Inc
Camber Consumer Care Inc: 30 products in the FDA NDC directory, labeler code 69230
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Camber Consumer Care Inc (labeler code 69230) lists 30 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 24 over the counter drugs, 6 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 30, 2025.
The request: Watch Camber Consumer Care Inc (FDA labeler code 69230): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 69230
- Products in commercial distribution
- 30
- Packages
- 95
- Finished drugs by generic name
- 15
- Prescription products
- 0
- Over the counter products
- 24
- Flagged as original packager
- 24 of 24 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- September 16, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 73.3% |
| Drugs for further processing | 6 | 20% |
| Over the counter monograph drugs | 2 | 6.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 24 | 80% |
| Drugs for further processing | 6 | 20% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Ibuprofen oral | 4 | 7 |
| Fexofenadine hcl | 4 | 39 |
| Loratadine | 3 | 125 |
| Famotidine | 2 | 138 |
| Esomeprazole magnesium | 1 | 77 |
| Polyethylene glycol 3350 | 1 | 67 |
| Naproxen sodium | 1 | 100 |
| Guaifenesin | 1 | 123 |
| Cetirizine hcl | 1 | 48 |
| Levonorgestrel | 1 | 31 |
| Cetirizine hydrochloride | 1 | 119 |
| Levocetirizine dihydrochloride | 1 | 52 |
| Loperamide hydrochloride and simethicone | 1 | 11 |
| Omeprazole | 1 | 106 |
| Acetaminophen dextromethorphan hbr | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 10 | 33.3% |
| Tablet, film coated | 9 | 30% |
| Suspension | 4 | 13.3% |
| Solution | 4 | 13.3% |
| Capsule, delayed release | 1 | 3.3% |
| Powder, for solution | 1 | 3.3% |
| Tablet, delayed release | 1 | 3.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Levonorgestrel | 69230-333 | Tablet | Generic drugs (ANDA) | September 30, 2025 |
| Adult Tussin | 69230-332 | Solution | Over the counter monograph drugs | May 19, 2025 |
| Day time high blood pressure cold and flu | 69230-331 | Solution | Over the counter monograph drugs | January 1, 2025 |
| Loratadine | 69230-323 | Tablet | Drugs for further processing | July 28, 2023 |
| Loratadine | 69230-323 | Tablet | Generic drugs (ANDA) | July 28, 2023 |
| Naproxen sodium | 69230-329 | Tablet, film coated | Generic drugs (ANDA) | October 28, 2022 |
| Loratadine | 69230-328 | Tablet | Generic drugs (ANDA) | July 31, 2022 |
| Fexofenadine HCl | 69230-201 | Tablet, film coated | Generic drugs (ANDA) | December 8, 2021 |
| Famotidine | 69230-327 | Tablet, film coated | Drugs for further processing | November 8, 2021 |
| Famotidine | 69230-327 | Tablet, film coated | Generic drugs (ANDA) | November 8, 2021 |
| Famotidine | 69230-326 | Tablet, film coated | Drugs for further processing | November 8, 2021 |
| Famotidine | 69230-326 | Tablet, film coated | Generic drugs (ANDA) | November 8, 2021 |
| Loperamide Hydrochloride and Simethicone | 69230-325 | Tablet | Generic drugs (ANDA) | June 17, 2021 |
| Loperamide hydrochloride and simethicone | 69230-325 | Tablet | Drugs for further processing | June 17, 2021 |
| Loratadine | 69230-322 | Solution | Generic drugs (ANDA) | May 7, 2021 |
| Polyethylene Glycol 3350 | 69230-324 | Powder, for solution | Generic drugs (ANDA) | April 14, 2021 |
| Levocetirizine dihydrochloride | 69230-321 | Tablet, film coated | Drugs for further processing | October 28, 2020 |
| Levocetirizine Dihydrochloride | 69230-321 | Tablet, film coated | Generic drugs (ANDA) | October 28, 2020 |
| Esomeprazole Magnesium | 69230-320 | Capsule, delayed release | Generic drugs (ANDA) | June 2, 2020 |
| Omeprazole | 69230-318 | Tablet, delayed release | Generic drugs (ANDA) | March 25, 2020 |
| Ibuprofen Oral | 69230-311 | Suspension | Generic drugs (ANDA) | September 18, 2019 |
| Ibuprofen Oral | 69230-310 | Suspension | Generic drugs (ANDA) | September 18, 2019 |
| Ibuprofen Oral | 69230-309 | Suspension | Generic drugs (ANDA) | September 18, 2019 |
| Childrens allergy relief | 69230-316 | Solution | Generic drugs (ANDA) | March 13, 2019 |
| Allergy Relief | 69230-304 | Tablet | Generic drugs (ANDA) | December 31, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.